TY - JOUR
T1 - Influence of race and sex on lipoprotein-associated phospholipase A2 levels
T2 - Observations from the Dallas Heart Study
AU - Brilakis, Emmanouil S
AU - Khera, Amit
AU - McGuire, Darren K
AU - See, Raphael
AU - Banerjee, Subhash
AU - Murphy, Sabina A.
AU - de Lemos, James A
N1 - Funding Information:
This study was supported in part by a research grant from GlaxoSmithkline. Emmanouil S. Brilakis receives support by the Clark R. Gregg Fund, Harris Methodist Health Foundation 6100 Western Place, Suite 1001, Fort Worth, TX 76107, USA, and by a Veterans Affairs VISN 17 startup award, Waco, Texas, USA. The Dallas Heart Study was funded by the Donald W. Reynolds Foundation (Las Vegas, NE) and was partially supported by USPHS GCRC grant #M01-RR00633 from NIH/NCRR-CR.
PY - 2008/7
Y1 - 2008/7
N2 - Aims: Most lipoprotein-associated phospholipase A2 (Lp-PLA2) studies included mainly white men. We sought to determine whether Lp-PLA2 levels differ according to race and sex. Methods: Lp-PLA2 mass and activity were measured in 3332 subjects age 30-65 participating in the Dallas Heart Study, a multiethnic, population-based, probability sample. Lp-PLA2 levels were compared between different race and sex groups. Results: Mean age was 45 ± 9 years and 44% were men; 30% were white, 17% hispanic, and 53% black. Mean Lp-PLA2 activity and mass were 146 ± 40 nmol/min/mL and 191 ± 60 ng/mL, respectively. Lp-PLA2 activity was lower in women compared with men (134 ± 35 vs. 161 ± 40, p = 0.001) and was lowest in black (136 ± 38), intermediate in hispanic (151 ± 36), and highest in white subjects (161 ± 39) (trend p = 0.0001). In multivariable linear regression models, after adjusting for age, body mass index (BMI), smoking, total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides and high sensitivity C-reactive protein (hsCRP), Lp-PLA2 activity was 19 nmol/min/mL higher in men vs. women (p < 0.001); compared with black subjects, adjusted Lp-PLA2 activity was 11 and 20 nmol/min/mL higher in white and hispanic subjects, respectively (both p < 0.001). Similar race and sex differences were observed for Lp-PLA2 mass. Conclusion: Race and sex independently influence Lp-PLA2 activity and mass. Thresholds to define Lp-PLA2 elevation may need to be sex and race specific.
AB - Aims: Most lipoprotein-associated phospholipase A2 (Lp-PLA2) studies included mainly white men. We sought to determine whether Lp-PLA2 levels differ according to race and sex. Methods: Lp-PLA2 mass and activity were measured in 3332 subjects age 30-65 participating in the Dallas Heart Study, a multiethnic, population-based, probability sample. Lp-PLA2 levels were compared between different race and sex groups. Results: Mean age was 45 ± 9 years and 44% were men; 30% were white, 17% hispanic, and 53% black. Mean Lp-PLA2 activity and mass were 146 ± 40 nmol/min/mL and 191 ± 60 ng/mL, respectively. Lp-PLA2 activity was lower in women compared with men (134 ± 35 vs. 161 ± 40, p = 0.001) and was lowest in black (136 ± 38), intermediate in hispanic (151 ± 36), and highest in white subjects (161 ± 39) (trend p = 0.0001). In multivariable linear regression models, after adjusting for age, body mass index (BMI), smoking, total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides and high sensitivity C-reactive protein (hsCRP), Lp-PLA2 activity was 19 nmol/min/mL higher in men vs. women (p < 0.001); compared with black subjects, adjusted Lp-PLA2 activity was 11 and 20 nmol/min/mL higher in white and hispanic subjects, respectively (both p < 0.001). Similar race and sex differences were observed for Lp-PLA2 mass. Conclusion: Race and sex independently influence Lp-PLA2 activity and mass. Thresholds to define Lp-PLA2 elevation may need to be sex and race specific.
KW - Lipoprotein-associated phospholipase A2
KW - Race
KW - Sex factors
UR - http://www.scopus.com/inward/record.url?scp=45249097117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45249097117&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2007.10.010
DO - 10.1016/j.atherosclerosis.2007.10.010
M3 - Article
C2 - 18061193
AN - SCOPUS:45249097117
SN - 0021-9150
VL - 199
SP - 110
EP - 115
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -